Your browser doesn't support javascript.
loading
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
O'Sullivan, Jennifer M; Hamblin, Angela; Yap, Christina; Fox, Sonia; Boucher, Rebecca; Panchal, Anesh; Alimam, Samah; Dreau, Helene; Howard, Kieran; Ware, Pauline; Cross, Nicholas C P; McMullin, Mary Frances; Harrison, Claire N; Mead, Adam J.
Afiliação
  • O'Sullivan JM; Department of Haematology, Guy's and St. Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom.
  • Hamblin A; Haematopoietic Stem Cell Biology Laboratory and.
  • Yap C; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Fox S; Oxford Molecular Diagnostics Centre, Oxford, United Kingdom.
  • Boucher R; National Institute for Health Research (NIHR) Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom.
  • Panchal A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Alimam S; The Institute of Cancer Research, London, United Kingdom.
  • Dreau H; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Howard K; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Ware P; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Cross NCP; Department of Haematology, Guy's and St. Thomas' National Health Service (NHS) Foundation Trust, London, United Kingdom.
  • McMullin MF; Oxford Molecular Diagnostics Centre, Oxford, United Kingdom.
  • Harrison CN; Oxford Molecular Diagnostics Centre, Oxford, United Kingdom.
  • Mead AJ; Oxford Molecular Diagnostics Centre, Oxford, United Kingdom.
Blood ; 134(23): 2107-2111, 2019 12 05.
Article em En | MEDLINE | ID: mdl-31578205
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Resistência a Medicamentos / Trombocitemia Essencial / Hidroxiureia Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Resistência a Medicamentos / Trombocitemia Essencial / Hidroxiureia Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido